Table 2.
Post-transplant features of human liver organoids in vivo.
| Database | Search term used | Hits | ||||
|---|---|---|---|---|---|---|
| PubMed | ((human liver organoid) OR (human liver bud)) AND (organoid transplant) | 43 | ||||
| Organoids | Recipient | Transplantatio n site | Purpose | Survival | Liver function | References |
| Human iPSC (hiPSC) derived liver bud organoids | Ganciclovir treated TK-NOG mice | Mesentery, cranium, subrenal capsule | Maturation, Engraftment, and Therapeutic | Improved | Albumin production+ | [20, 78, 79, 83, 88] |
| Human EpCAM+ duct cell derived organoids | Retrorsine/CCl4-treated Balbc/nude mice | Intrasplenic injection | Maturation and Engraftment | — | Albumin production+ | [41] |
| 3D printed human LBs | Wild type Lewis rats | Liver | Maturation and Engraftment | — | Albumin production+ | [101] |
| hiPSC derived liver bud organoids | NOD/SCID mice | Cranium | Vascularization | — | Albumin production+ | [68] |
| hiPSC derived liver organoids | Diphtheria toxin-induced Alb-TRECK/SCID mice | Subrenal capsule | Therapeutic | Improved | Serum ALT and AST levels decreased | [85] |
| hiPSC derived liver organoids | Alb-TRECK/SCID mice | Subrenal capsule | Therapeutic | Improved | Albumin production+ | [95] |
| hiPSC derived liver organoids | Retrorsine treated FNRG mice | Intrasplenic injection | Therapeutic | — | Albumin production+ | [65] |
| hiPSC derived HBPOs | NSG mice | Subrenal capsule | Maturation and Engraftment | — | — | [71] |
| hiPSC derived liver organoids | NSG mice | Intrsplenic injection | Therapeutic | — | Albumin production+ | [70] |
| hiPSC derived liver organoids | Athymice nude rats | Intrsplenic injection | Therapeutic | Improved | Serum ALT and AST levels decreased | [93] |
| hiPSC derived liver organoids | Immunocompromised rats | Liver, intraportal | Therapeutic | Improved | Albumin production+ | [80] |
| hiPSC derived liver organoids | Piglets | Portal vein injection | Safety and Efficacy | — | Albumin production+ | [104] |
| Human amniotic mesenchymal stem cells | CCl4-treated CD1 mice | Intrsplenic injection | Therapeutic | Improved | Albumin production+ | [106] |
| hPSC derived liver organoids | NSG mice | Subrenal capsule | Maturation and Engraftment | — | Albumin production+ | [86] |
| hiPSC-derived cholangiocyte organoids | NSG mice, ex vivo human liver | Intrahepatic ducts | Therapeutic | Improved | Bile production+ | [81, 82] |
| HLA mismatched hiPSC liver bud organoids | NOG-HLA-A2Tg mice | Liver | Disease Modeling | — | Albumin production+ | [90] |